European Journal of Surgical Oncology
Volume 33 , Pages S24-S34 , December 2007

Monoclonal antibodies in the treatment of advanced colorectal cancer

,Accepted 26 September 2007.

References 

  1. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–1214
  2. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand–receptor interactions. FEBS Lett. 1997;410:83–86
  3. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376:599–602
  4. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal. 2000;1:12–21
  5. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2–neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7:1850–1855
  6. Steele RJ, Kelly P, Ellul B, Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg. 1990;77(12):1352–1354
  7. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol. 1997;24(6):602–615
  8. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem. 1984;259:7755–7760
  9. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res. 2000;6:747–753
  10. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res. 2000;6:2166–2174
  11. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002;8:994–1003
  12. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol. 2001;20:3a
  13. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  15. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol. 2003;22:204;[abstract 817]
  16. Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 237].
  17. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3549]
  18. Souglakos J, Androulakis N, Tzardi M, et al. Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) (CAPOX) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after oxaliplatin-based chemotherapy. ASCO Gastrointestinal Cancer Symposium. 2006;[abstract 235]
  19. Diaz-Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): an international phase II study. Proc Am Soc Clin Oncol. 2005;23:16S;[abstract 3535]
  20. Colucci G, Giuliani F, Mattioli R, et al. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3559]
  21. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX)±cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3509]
  22. Borner M, Mingrone W, Koeberle D, et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3551]
  23. Lang I, Zaluski J, Changchein CR, et al. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Preliminary safety results (CRYSTAL). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3555]
  24. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan, fluorouracil, and leucoverin in colorectal cancer that express the epidermal growth factor receptor. Proc Am Soc Clin Oncol. 2002;21:[abstract 536]
  25. Folprecht G, Lutz M, Schefski P, et al. Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). ASCO Gastrointestinal Cancers Symposium, 2004 [abstract 283].
  26. Rougier P, Raoul J-L, Van Laethem J-L, et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2004;22:14S;[abstract 3513]
  27. Hohler T. Phase I/II study of cetuximab combined with 5-fluorouracil/leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer. Presented at the 30th European Society of Medical Oncology Congress, Vienna, Austria; October 29 to November 2004.
  28. Dakhil S, Cosgriff T, Headley D, Badarinath S, Boccia RV. Cetuximab+FOLFOX6 as first-line therapy for metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3557]
  29. Tabernero J, Cervantes A, Martinelli E, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3085]
  30. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292–4302
  31. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol. 2005;23:5235–5246
  32. Hecht J, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol. 2004;22:14S;[abstract 3511]
  33. Van Cutsem E, Peeters M, Siena S, et al. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer. World Congress on Gastrointestinal Cancer, 2006 [abstract O-027].
  34. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004;22:175–184
  35. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803
  36. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685–693
  37. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027
  38. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–4380
  39. Gray MJ, Wey JS, Belcheva A, et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res. 2005;65(9):3664–3670
  40. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–844
  41. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–1039
  42. Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs. 2002;11(12):1715–1736
  43. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105(8):R15–R24
  44. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60–65
  45. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–3705
  46. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342
  47. Giantonio BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AV. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol. 2006;17(9):1399–1403
  48. Kopetz S, Eng C, Adinin RB, et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3579]
  49. Sobrero A, Carrion RP, Chiara S, et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3544]
  50. Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3506]
  51. Giantonio B, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol. 2005;23:1S;[abstract 2]
  52. Cassidy J, Diaz Rubio E, Scheithauer W, et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase III trial of XELOX vs. FOLFOX4 1 bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol. 2006;17(Suppl. 9):[abstract LBA3]
  53. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 238].
  54. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3510]
  55. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3536]
  56. Berry SR, Cunningham D, Michael M, et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC – first B.E.A. Trial. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3534]
  57. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24(21):3354–3360
  58. Ciardello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6:3739–3747
  59. Saltz LB, Lenz H, Hochster S, et al. Randomised phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol. 2005;23:16S;[abstract 3508]
  60. Baselga J, Schöffski P, Rojo F, et al. A phase I pharmacokinetic and molecular pharmacodynamic of the combination of two anti-EGFR therapies, the monoclonal antibody cetuximab, and the tyrosine kinase inhibitor gefitinib, in patients with advanced colorectal, head and neck, and non-small cell lung cancer. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3006]
  61. Julie C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC intergroup phase III study 40983. ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 241].
  62. Gruenberger B, Scheithauer W, Tamandl D, et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3546]
  63. Bendell JC, Fernando N, Morse M, et al. A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2006;24:18S;[abstract 3541]
  64. Kabbinavar F, Schultz J, McCleod M, et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol. 2004;22:14S;[abstract 3516]

PII: S0748-7983(07)00544-6

doi: 10.1016/j.ejso.2007.09.025

European Journal of Surgical Oncology
Volume 33 , Pages S24-S34 , December 2007

Article Tools

* Image Usage & Resolution